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ABSTRACT
The release of infectious hepatitis C virus (HCV) particles from infected cells remains poorly characterized. We previously dem-
onstrated that virus release is dependent on the endosomal sorting complex required for transport (ESCRT). Here, we show a
critical role of trans-Golgi network (TGN)-endosome trafficking during the assembly, but principally the secretion, of infectious
virus. This was demonstrated by both small interfering RNA (siRNA)-mediated silencing of TGN-associated adaptor proteins
and a panel of dominant negative (DN) Rab GTPases involved in TGN-endosome trafficking steps. Importantly, interfering with
factors critical for HCV release did not have a concomitant effect on secretion of triglycerides, ApoB, or ApoE, indicating that
particles are likely released fromHuh7 cells via pathways distinct from that of very-low-density lipoprotein (VLDL). Finally, we
show that HCVNS2 perturbs TGN architecture, redistributing TGNmembranes to closely associate with HCV core protein re-
siding on lipid droplets. These findings support the notion that HCV hijacks TGN-endosome trafficking to facilitate particle as-
sembly and release. Moreover, although essential for assembly and infectivity, the trafficking of mature virions is seemingly in-
dependent of host lipoproteins.
IMPORTANCE
Themechanisms by which infectious hepatitis C virus particles are assembled and released from the cell are poorly understood.
We show that the virus subverts host cell trafficking pathways to effect the release of virus particles and disrupts the structure of
the Golgi apparatus, a key cellular organelle involved in secretion. In addition, we demonstrate that the mechanisms used by the
virus to exit the cell are distinct from those used by the cell to release lipoproteins, suggesting that the virus effects a unique
modification to cellular trafficking pathways.
Hepatitis C virus (HCV) is a major cause of chronic hepatitis,which can progress to cirrhosis and hepatocellular carci-
noma. The recent development of direct-acting antivirals (DAA)
(1), exemplified by the recently FDA-approved polymerase inhib-
itor sofosbuvir, promises much improved treatment of HCV.
However, high drug costs, coupled with concerns over resistance,
require a deeper understanding of HCV biology in order to iden-
tify novel antiviral targets.
HCV is an enveloped virus with a 9.6-kb positive-sense single-
stranded RNA genome, encoding a 3,000-amino-acid polyprotein
precursor which is cleaved by host and viral proteases into the
structural proteins core, envelope proteins E1 and E2, and p7 and
the nonstructural (NS) proteins NS2, NS3, NS4A, NS4B, NS5A,
and NS5B. Core protein, the principle constituent of the viral
capsid, is targeted to lipid droplets (LDs) (2–4), implying a role for
these lipid storage organelles during HCV assembly. The E1 and
E2 glycoproteins form a heterodimeric complex in the viral enve-
lope. NS5A and viral RNA colocalize with core protein in proxim-
ity to LDs (5), and an interaction betweenNS5A and core is critical
for the production of infectious virions (6). Furthermore, NS2
interacts with p7, E2, NS3, andNS5A, coordinating these proteins
to bring them into proximity with LDs during virion assembly
(7–10). A late-acting, postassembly role for NS2 during virion
release has also been described previously (8, 11, 12).
The cellular pathways involved in virion assembly and release
remain poorly understood. Assembly of infectious intracellular
HCVvirions occurs in close proximity to LDs and is dependent on
factors required during very-low-density lipoprotein (VLDL) as-
sembly, including DGAT1 (13), apolipoprotein B-100 (ApoB)
(14), and ApoE (15). A role for VLDL pathways in the subsequent
release ofHCVparticles has therefore been proposed althoughnot
formerly demonstrated (reviewed in reference 16).More recently,
we, along with others, demonstrated that HCV release is depen-
dent on components of the endosomal sorting complex required
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for transport (ESCRT), suggesting that HCV release is dependent
on endosomal compartments (17, 18). In addition, early endo-
some proteins such as Rab5 have been shown to be required for
virus genome replication, suggesting that HCV is dependent on
this compartment at multiple stages in the virus life cycle (19, 20).
Here, we further dissect the endosomal routes of HCV egress.
We show that trans-Golgi network (TGN)-associated adaptors
play a pivotal role during both HCV assembly and release. Fur-
thermore, a TGN-secretory endosomal pathway, defined by dom-
inant negative (DN) Rab-GTPasemutants, mediates the release of
infectious virions but not that of triglycerides (TGs) or ApoE, the
principle components of VLDL. We also show that the TGN re-
distribution observed within HCV-infected cells is driven by NS2
but only when it is expressed in the context of a functional HCV
replicase. Thus, our data support the idea that release of infectious
HCV occurs via a TGN-endosome secretory pathway that is dis-
tinct from that of VLDL within infected Huh7 cells.
MATERIALS AND METHODS
Cell culture.Huh7 cells were cultured as described previously (21). Sub-
genomic replicon-harboring cell lines were generated and maintained as
described previously (22).
DNA constructs and transfection. Wild-type (WT) and dominant
negative (DN) Rabs were expressed using a pEGFP-C1 or pECFP-C1
(where EGFP is enhanced green fluorescent protein and ECFP is en-
hanced cyan fluorescent protein) vector and have been described previ-
ously (23). A total of 2 105Huh7 cells in one well of a six-well plate were
transfected using polyethylenimine (PEI) (Polysciences, Inc.) according
to the manufacturer’s instructions. To quantify absolute numbers of
transfected cells, plates were visualized with an IncuCyte Zoom system
(Essen Bioscience) at 24 h posttransfection, and the number of green
objects per well was calculated. Filter parameters were set to exclude ob-
jects with 200-m2 and 3,000-m2 areas, thereby excluding cellular
debris. Background threshold was set to a minimum of 5.0 green cali-
brated units (GCU) and was increased where necessary until an untrans-
fected control well had a score of zero.
Production of infectiousHCV.A total of 10g of in vitro-transcribed
(Promega) JFH-1, Jc1 (24), or J6/JFH-1luc (a luciferase-expressing J6/
JFH-1 chimeric virus) (25) transcripts was electroporated intoHuh7 cells,
which were washed and resuspended in diethyl pyrocarbonate (DEPC)-
treated phosphate-buffered saline (PBS) (8  106 cells; 400 l). Electro-
porationwas carried out using a Bio-RadGene Pulser II at 975F and 270
V in a 4-mm cuvette. Cells were plated into T175 flasks in 12 ml of me-
dium, which was harvested/replenished every 24 h to generate pooled
virus stocks.
siRNAs and transfection. Validated Silencer Select small interfering
RNAs (siRNAs) (Life Technologies) were used to silence AP1MI, AP2MI,
GGA1,GGA2, andGGA3.Huh7 cells were seeded (1 105 cells) into each
well of a six-well plate and transfected with 150 pmol of each siRNA,
including a scrambled RNA control, using Lipofectamine RNAiMax (Life
Technologies) according to themanufacturer’s instructions. At 48 h post-
transfection, the supernatant and cell lysate were collected for analysis,
and/or cells were infected with virus as described below.
Quantification of effects on HCV particle production and release.
Following transfection (see above), cells were infected at a multiplicity of
infection (MOI) of 0.2 focus-forming units (FFU)/cell for 24 h in com-
plete Dulbecco’s modified Eagle’s medium (DMEM). Following two
washes in PBS, released virus was collected in serum-free medium for 24
h. Clarified culture supernatant infectivity was determined by focus-
forming assay. This was also performed for intracellular infectivity follow-
ing resuspension of cells in 50l of PBS, five repetitive freeze-thaw cycles,
and clarification at 2,800  g in a microcentrifuge for 5 min. Data are
expressed as means and standard errors. Statistical significance was deter-
mined using a paired Student t test for comparison of two sets of data or a
one-way analysis of variance (ANOVA) with a Bonferroni test when data
for more than two Rab constructs were compared against the GFP-alone
controls. A P value of0.05 was deemed significant.
Quantificationof secreted triglyceride/ApoE.Triglyceride content of
heat-inactivated (65°C, 15min) phenol red and serum-free culture super-
natants was assessed using a colorimetric lipase-based assay that hydro-
lyzes triglycerides to free glycerol, according to the manufacturer’s in-
structions (Sigma). ForWestern blot analysis of ApoE levels, supernatants
were precipitated withmethanol at 4°C overnight; thereafter, precipitated
lipoproteinswere pelleted at 10,000 g for 10min and resuspended in 1
Laemmli buffer forWestern blot analysis. Cells were lysed inGlasgow lysis
buffer (GLB; 10mMPIPES [piperazine-N,N=-bis(2-ethanesulfonic acid]-
KOH, pH 7.2, 120 mM KCl, 30 mM NaCl, 5 mM MgCl2, 1% [vol/vol]
TritonX-100, and 10% [vol/vol] glycerol) plus protease inhibitors (Roche
Complete) and phosphatase inhibitors (2mMNa3VO4, 5mMNaF, 5mM
Na4P2O7), and 10 g of total protein was analyzed by Western blotting.
SecretedApoB andApoEwere also detected and quantifiedwith commer-
cial enzyme-linked immunosorbent assay (ELISA) kits (AlerCHEK).
Briefly, supernatants were diluted 1:10with diluent (ApoBELISA) or used
undiluted (ApoE ELISA) and allowed to adhere to the plate for 45 min.
After plates were thoroughly washed, horseradish peroxidase (HRP)-con-
jugated goat anti-human ApoB/ApoE secondary antibody was added and
allowed to incubate for 45 min. Wells were washed and incubated with
3,3=,5,5=-tetramethylbenzidine (TMB)-peroxide solution for 15 min be-
fore the reaction was terminated with sulfuric acid. Absorbance was read
at 450 nm, and sample values were extrapolated from a positive-control
standard curve.
Replication assays. Rab-GFP/CFP-expressing or siRNA-treated cells
were infected with J6/JFH-1luc at an MOI of 0.2 FFU/cell as described
above prior to lysis in 400 l of passive lysis buffer (Promega). Renilla
luciferase activity was measured using dual-luciferase Stop and Glo re-
agent (Promega) using a luminometer (EG&G Berthold). All assays were
performed in triplicate, and each experiment was repeated a minimum of
three times. All data are expressed as means and standard errors.
Western blotting. Infected or transfected cells were lysed in GLB as
described above, and 10 g of protein was resolved by SDS-PAGE. Pro-
teins were transferred onto polyvinylidene difluoride (PVDF) membrane
(Millipore) using a Bio-Rad semidry transfer apparatus and then probed
with mouse anti-ApoE antibody (Sigma or Abcam), polyclonal rabbit
anti-core protein (kind gift from John McLauchlan, Centre for Virus
Research, Glasgow, Scotland), rabbit polyclonal anti-AP1M1, -AP2MI,
-GGA1, -GGA2, or -GGA3 (Abcam), mouse monoclonal anti-EGFP, or
mouse anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
(GeneTex). Washed membranes were incubated with HRP-conjugated
donkey anti-sheep, donkey anti-rabbit, or goat anti-mouse secondary an-
tibody (Sigma) and visualized using an in-house enhanced chemilumi-
nescence system.
Immunofluorescence microscopy. Cells grown on glass coverslips
were fixed for 10 min with 3% (vol/vol) paraformaldehyde (PFA) in PBS
at room temperature or in ice-cold methanol, followed by permeabiliza-
tion in ice-coldmethanol-acetone for 10min. Cells were washedwith PBS
and blocked in PBS–1% bovine serum albumin (BSA) for 30 min prior to
incubation with primary antibodies for 1 h in PBS–1% BSA with poly-
clonal rabbit anti-core protein, sheep polyclonal anti-TGN46 (kind gift
from Sreenivasan Ponnambalam, University of Leeds) (0.5 g/ml),
mousemonoclonal anti-AP1 (Sigma), rabbit polyclonal anti-NS5A serum
(kind gift from Ralf Bartenschlager, University of Heidelberg), rabbit
polyclonal anti-AP2M1 (Abcam) ormousemonoclonal AP33 anti-E2 an-
tibody (provided by Genentech). Washed cells were then labeled using an
appropriate Alexa Fluor 488/594/647-conjugated secondary antibody
(Invitrogen). Cells were washed and mounted onto microscope slides
using Citifluor (Agar Scientific) and then viewed on a Zeiss 510-META
laser scanning confocal microscope under an oil immersion 63 objec-
tive lens (numerical aperture, 1.40). Alexa Fluor 488 dye (494-nm excita-
tion; 519-nm emission) was excited using an argon laser fitted with
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488-nm filters, Alexa Fluor 594 dye (550-nm excitation; 570-nm emis-
sion) was excited using a helium-neon laser fittedwith 543-nmfilters, and
Alexa Fluor 647 dye (650-nm excitation; 670-nm emission) was excited
using a helium-neon laser fitted with 633-nm filters. Images displayed are
representative and are displayed as single optical sections.
RESULTS
HCV particle assembly and release require specific TGN adap-
tors. Given the emerging evidence implicating a role for the en-
dosomal trafficking machinery during HCV egress, we employed
siRNA targeting of key TGN-endosomal trafficking proteins, in-
cluding the 1 subunits of the TGN-resident clathrin adaptor
complex AP1 and the endocytic adaptor AP2 (termedAP1M1 and
AP2M1), as well as the Golgi-localized gamma adaptin ear-con-
taining, ARF-binding (GGA) proteins GGA1, GGA2, and GGA3,
to assess their roles in virus assembly/egress. Huh7 cells trans-
fected with an siRNA were subsequently infected either with
JFH-1 to assess infectious particle production or with a luciferase-
expressing J6/JFH-1 chimeric virus (J6/JFH-1luc) to measure ge-
nome replication.
As expected, an siRNA targeted to the NS5B coding region of
the virus genome efficiently blocked genome replication whereas
silencing of individual TGN trafficking proteins had no significant
effects (Fig. 1A). In contrast, the importance of TGN-endosomal
trafficking to both virion assembly and egress was evident as the
siRNA mediated disruption of intracellular and secreted infectiv-
ity. Depletion of AP1M1 had no effect on intracellular infectivity
(Fig. 1B) but inhibited release (44%  2.5% reduction in extra-
cellular infectivity) (Fig. 1C). Similar data have recently been re-
ported with the silencing of the TGN-endosome adaptor AP1
gamma subunit (AP1G1) in JFH-1-infected hepatocytes (26).
This same trend in infectivity was observed when GGA2 was si-
lenced (64%  3.5% reduction in extracellular infectivity) (Fig.
1C), suggesting that both this and AP1M1 strongly influence the
delivery of assembled virions into the secretory pathway. In con-
trast, a lack of GGA3 resulted in significant reductions in both
intracellular (87%  4% reduction) (Fig. 1B) and extracellular
(78% 3% reduction) (Fig. 1C) infectivity, suggesting that virus
assembly had been disrupted. Intriguingly, silencing of GGA1
yielded an unusual phenotype whereby intracellular infectivity
was reproducibly diminished (60%  4.5% reduction) whereas
that in the secreted compartment was unaltered (Fig. 1B and C).
We further consider the implications of this result in the discus-
sion. In contrast to previous studies (27) and further supporting a
TGN-mediated pathway of virus egress, knockdown of AP2M1
(an endocytic adaptor) had no effect on the virus life cycle. Effi-
cient silencing of individual proteins was confirmed in Huh7 cells
by Western blotting (Fig. 1D). This is in agreement with another
more recent study in which knockdown of the AP2M1 was shown
to have no effect on extracellular HCV RNA release (26). To-
gether, these data strongly support the critical importance of the
TGNand its associated adaptors duringHCVparticle production.
Secretory, but not endocytic, Rab-GTPases control the re-
lease of HCV particles. Given the clear importance of TGN-en-
dosomal adaptors during particle production, we reasoned that
virions likely follow a defined endosomal pathway during
egress. To map this pathway, we exploited the large family of
Rab GTPases (60members), individual members of which gov-
ern specific membrane trafficking steps. Huh7 cells were trans-
fected with a panel of plasmids encoding wild-type or DN Rab
proteins as GFP/CFP fusions prior to infection with JFH-1 or J6/
JFH-1luc. Effects on intracellular/secreted infectivity or replica-
tion (assayed by luciferase activity) were calculated by dividing the
value obtained in the presence of the DN by that obtained for the
corresponding wild-type Rab; values of less than 1 thus repre-
sented a defect mediated by the DN Rab. We first verified that
different stages of the HCV life cycle could be discriminated using
DN mutants of cellular cofactors: Rab5, which interacts with
NS4B and is required for HCV RNA replication (20), and the
AAA-family ATPase VPS4, whichmediates budding/release of as-
sembled HCV particles via recycling of ESCRT-III (17, 18). Reas-
suringly, DN Rab5 reduced HCV replication (61% 10% inhibi-
tion) with concomitant effects on total infectivity (62%  9%
inhibition), whereas DNVPS4 specifically reduced secreted infec-
tivity (64%  8% inhibition) with no effect on replication or
intracellular infectivity (Fig. 2A).
We therefore extended our analysis to include Rab proteins
governing either endocytic/recycling (Rab7, -9, -11, and -35) or
secretory/exocytic (Rab3a, -8b, -13, -23, -27, -32, -33, and -37)
pathways (Fig. 2). No effects upon replication (and by inference,
virus entry) (Fig. 2B) or on the production of intracellular parti-
cles (Fig. 2C) were apparent, yet several DN secretory/exocytic
Rabs significantly inhibited the release of infectious HCV; DN
Rab8b, -13, -23, -27, -32, and -33 proteins caused60% decrease
in extracellular titers (Fig. 2D). Endocytic/recycling Rab proteins
lacked an appreciable role during particle assembly or egress.
Comparable expression was confirmed for a subset of the Rab
proteins (those expressed as GFP fusions) by Western blotting
(Fig. 2E); while overall levels expectedly varied to some extent
between Rabs, variation within pairs of WT/DN constructs was
similar. Thus, whereDNRabs affected particle release (e.g., Rab23
and -27), it is highly unlikely that this resulted from increased
expression relative to the WT counterpart. Furthermore, we con-
firmed that transfected cells were not somehow rendered refrac-
tory to infection by quantifying the proportion of NS5A-express-
ing cells that were also GFP positive using the IncuCyte Zoom
system (28). This revealed similar levels of infection in all cases
except where the DN endocytic Rab5 was expressed, which might
be expected, given its role during replication, as discussed above.
Moreover, given that only a subset of infected cells expressed
dominant negative proteins, it is likely that our population-based
infectivity measures in fact underestimate the effects on release at
the level of individual transfected cells.We therefore conclude that
the trafficking/release of assembled, infectious HCV particles in-
volves transfer through the TGN into a defined secretory endo-
somal pathway within Huh7 cells.
Perturbation of the TGN/endosomal axis of HCV assembly/
release does not affect VLDL secretion. Current models assume
that HCV co-opts the VLDL secretory machinery to effect the
release of infectious virions, and this assumption is based upon
the essential role for factors involved in VLDL biogenesis during
particle assembly and the modulation of VLDL synthesis and se-
cretion by infected cells (29). However, direct evidence for this
secretory pathway is lacking, and recent studies show that clath-
rin-mediated stages of virion egress appear distinct to ApoE secre-
tion; knockdown of either clathrin or its adaptor AP1 impaired
virus secretion but had no effect on extracellular ApoB or ApoE
(26). Hence, in order to reconcile our observed TGN/endosomal
dependence of secretion with these observations, it was necessary
to formally investigate whether knockdown/disruption of TGN
HCV Release Is VLDL Independent











adaptors or Rabs led to disruption of VLDL secretion. To test this,
experiments were repeated with cells grown under serum-free
conditions to permit directmeasurement of releasedApoE, ApoB,
and triglyceride, which comprise themajor elements of theVLDL-
like particles generated by Huh7 cells (30).
We first examined whether ApoE release was affected by
knockdown of factors that reduced the accumulation of intracel-
lular HCV infectivity (GGA1 and -3), as well as that of the release-
specific AP1M1 and GGA2. Levels of both intracellular and se-
creted ApoE were unaffected, with the exception of a modest
increase in secreted ApoE in the case of GGA1 knockdown (Fig.
3A). This was expected as GGA1 has been shown to specifically
associate with endocytosis of the ApoE receptor, LR11/SorLA
(31). We then quantified the effects of perturbing Rab protein
function on the secretion of the major constituent of VLDL, tri-
glyceride (TG). Again, no effect on TG release was observed, re-
gardless of whether DN Rab proteins affected HCV particle pro-
duction or not (Fig. 3B). Last, we directly quantified the secretion
of both ApoE and ApoB using ELISAs; as shown in Fig. 3C, levels
of bothApoB andApoE secretionwere inherently variable, yet this
FIG 1 Effects of siRNA knockdown of Golgi apparatus-endosome trafficking proteins on HCV genome replication and virus production. Huh7 cells were
transfected with siRNAs for each of the five targets or with a scrambled RNA control and incubated for 48 h, followed by infection with JFH-1 at an MOI of 0.2
for 48 h. (A) For the assessment of HCV genome replication, cells were infected with J6/JFH-1luc at an MOI of 0.2 for 48 h prior to measurement of luciferase
activity. Extracellular (B) and intracellular (C) infectivity were then assessed by focus-forming assay. All data are expressed as the ratio of absolute values obtained
in the presence of the scrambled RNA control to those of the siRNA target sample and are presented as means plus standard errors. **, P 0.05. (D) At 72 h
posttransfection, cells transfected with either a control scrambled siRNA (Cont.) or targeted siRNAs, as indicated, were lysed and probed for each target protein
and GAPDH, as an internal control, by Western blot analysis.
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FIG 2 HCV release is controlled by secretory, but not endocytic, Rab-GTPases. Huh7 cells were transfected with plasmids expressing either wild-type or DN
versions of the indicated proteins for 24 h, followed by infection with JFH-1 at anMOI of 0.2 for 24 h. Infectivity was determined by focus-forming assay. For the
assessment of HCV genome replication, cells were infected with J6/JFH-1luc at anMOI of 0.2 for 48 h prior tomeasurement of luciferase activity. (A) Validation
of the assay using previously characterized controls: VPS4, which inhibits assembly, andRab5, which inhibits genome replication. (B toD)Results of a replication
assay and intracellular and extracellular infectivity assays are shown, as indicated. All assays were performed in triplicate, and each experiment was repeated a
minimum of three times. All data are expressed as the ratio of absolute values obtained in the presence of the wild-type (WT) to those of the DN Rab construct
(DN/WT) and are presented as means and standard errors. **, P  0.05. (E) To analyze Rab protein expression, the indicated cell lysates were subjected to
Western blotting for EGFP. LaneM,molecularmassmarker. (F) Todetermine the efficiency of the transfection/infection procedure, the numbers of infected cells
(NS5Apositive) thatwere alsoGFPpositiveweremanually counted, and results are displayed as a percentage of the total number of infected cells. A representative
image of DN Rab7 transfected cells is shown for illustrative purposes.
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variation did not correlate with observed effects upon secreted
infectivity (compare Fig. 2D and 3C).
Next, we took the converse approach of inhibiting VLDL se-
cretion usingmonensin and askingwhether this adversely affected
the secretion of HCV proteins into the extracellular milieu (Fig.
4). Monensin effectively reduced extracellular ApoE levels and led
to the concomitant intracellular accumulation of ApoE, confirm-
ing a block to secretion.Under these conditions therewas no effect
on either intracellular or extracellular levels of core protein. This is
consistent with a recent publication demonstrating inhibitory ef-
fects ofmonensin onHCV entry but a lack of effect on assembly or
release of infectious virus (32). Thus, while VLDL components
clearly play a vital role during virion morphogenesis, the TGN/
endosomal pathways specifically concernedwithHCV trafficking/
release appear separate from those governing VLDL secretion.
TGNmorphology and trafficking are altered duringHCV in-
fection.Given the role of the TGN during HCV assembly/release,
we next assessed changes to TGN membrane architecture during
HCV infection. Consistent with previous studies (33), we found
that the TGNmarkers TGN46 and AP1 exhibited a dispersed dis-
tribution in JFH-1-infected cells compared to that in surrounding
uninfected cells, which retained a characteristic perinuclear Golgi
“stack” (Fig. 5A). TGN redistribution was further confirmed by
FIG 3 Inhibition of TGN-endosomal trafficking proteins or secretory Rabs does not affect VLDL secretion. (A) To assess ApoE trafficking and secretion in
siRNA-transfected cells, ApoE was methanol precipitated from the supernatants and assessed by Western blot analysis. Cell lysates were also probed for
intracellular ApoE by Western blot analysis. (B) Secreted triglyceride levels were assessed in the culture supernatants from the HCV-infected cells from the
experiment shown in Fig. 2 using a colorimetric lipase-based assay that hydrolyzes triglycerides to free glycerol. NS, not significant. (C) To assess secretion of
ApoE and ApoB from WT or DN plasmid-expressing cells, culture supernatants were analyzed by ELISA.
FIG 4 Core protein secretion can be separated from apolipoprotein secretion.
JFH-1-infected or uninfected cells were treated with monensin (2 M) for 18
h. Lysates or precipitated supernatants were analyzed by Western blotting for
the indicated proteins.
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staining infected cells for the TGN-endosome shuttling protein
mannose 6-phosphate receptor (MPR) (34, 35). MPR was again
more widely distributed within infected cells than in adjacent na-
ive cells. TGN redistribution was dependent on productive virus
entry and replication as infection with heat-inactivated virus pre-
vented alteration of TGN46 or AP1 distribution (Fig. 5B). These
data support the observation that HCV disperses the TGN and
alters the normal trafficking profile of TGN-resident proteins.
TGNmembranes are contiguous with putative HCV assem-
bly sites in infected cells. We noted that in JFH-1-infected cells,
the pattern of TGN staining was reminiscent of that previously
reported for LDs. To investigate this further, we costained JFH-1-
infected cells with antibodies to TGN46 and core protein, together
with the lipid reactive dye BODIPY (dipyrromethene boron diflu-
oride) (Fig. 6A). All three components showed contiguous distri-
butions such that the redistributed TGN compartments were
juxtaposed with both LDs and core protein within infected cells
(Fig. 6A), but not in uninfected cells (Fig. 6B), in a pattern
reminiscent of the coating of LDs reported for core protein and
NS5A (5, 36, 37).
We considered that the redistribution of the TGN results in
juxtaposition of this compartmentwithHCVassembly sites (2, 5).
While E2 and the core protein were only partially contiguous with
each other, noticeable clustering of both proteins occurred at ar-
eas positive for TGN46 (Fig. 6C). Such clustering also occurred for
ApoE (Fig. 6D) andmost likely represents the sites of virus assem-
bly. We therefore consider that TGN membrane redistribution
within close proximity to LDs occurs during virus infection, po-
tentially linking regions of virion assembly with the secretory
pathways required for HCV egress.
NS2-mediated TGN alterations within infected cells require
a functional HCV replicase. Given the role of NS2 in coordinat-
ingNS and structural proteins during virion assembly, we hypoth-
esized that NS2 might be responsible for the TGN rearrange-
ments. To test this, we expressed either the structural proteins
(core protein-p7 expression), the minimal HCV replicase (NS3 to
NS5B [NS3-5B] replicon), or the complete nonstructural protein
repertoire (NS2-5B replicon) (38) within Huh7 cells. Strikingly,
compared to results in JFH-1-infected cells (Fig. 7A), the expres-
sion of core-p7 alone displayed no discernible effects on TGN
architecture, and a mutually exclusive staining pattern for core
protein and TGN46 was observed (Fig. 7B). Similarly, the TGN
was not redistributed within cells expressing an NS3-5B replicon
although some overlap of NS5A (a surrogate marker for replica-
tion complexes) with TGN46 was apparent (Fig. 7C). However,
cells expressing an NS2-5B replicon recapitulated the TGN rear-
rangements observed during full virus infection (Fig. 7D). TGN
rearrangements required continuous HCV gene expression and
were not a clonal selection artifact as a normal TGN appearance
was restored within NS2-5B replicon cells cured by interferon
treatment (Fig. 7E). Furthermore, the context of NS2 expression
within the viral replicase appeared critical as NS2 fused to GFP
expressed alone did not induce redistribution of the TGN (Fig.
7F), as was the case for control cells transfected with GFP alone
(Fig. 8G). Finally, we assessed whether the functionally conserved
NS2 Ser168might play a role during this process; Ser168 is a target
for phosphorylation by casein kinase II (39) and strongly influ-
ences both infectious particle production (8, 40) and NS5A inter-
actions (38). Replicons containing the S168A mutation still in-
duced TGN rearrangements (Fig. 8), indicating that this process
requires additional NS2 functional determinants. Furthermore,
these replicons were based on the genotype 1b culture-adapted
FK5.1 sequence (22), indicating that the ability to induce TGN
rearrangements is not restricted to the genotype 2a JFH-1 isolate.
DISCUSSION
The starting point for this study was the critical importance of
TGN-endosomal adaptors during HCV particle production.
Silencing of the 1 subunit of AP1, an adaptor involved in TGN-
endosome trafficking, inhibited virus egress but did not affect vi-
FIG 5 HCV infection alters TGN morphology. (A) Huh7 cells were infected
with JFH-1, fixed, and permeabilized prior to staining with a rabbit anti-core
antibody and Alexa Fluor 594-conjugated anti-mouse secondary antibody.
Endogenous TGN46, AP1, andM6PRwere detected using either a sheep poly-
clonal anti-TGN46 ormousemonoclonal anti-AP1 andM6PR antibodies with
Alexa Fluor 488-conjugated anti-sheep or anti-mouse secondary antibodies.
(B) Virus stocks were heat inactivated at 65°C for 30 min prior to infection of
Huh7 cells, and TGN and AP1 staining were assessed as described for panel A.
Representative wide-field images are shown. Scale bar, 10 m.
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rus replication/assembly. Encouragingly, this same result has been
achieved with the silencing of the 1 subunit of AP1 (26). Our
study also agrees with the findings of Benedicto and colleagues
(26) in that no reduction of infectivity was observed when the 1
subunit of AP2 (an endocytic adaptor) was silenced, making
TGN-endosome trafficking the key route of HCV JFH-1 egress
(Fig. 1). However, a previous study (27) showed that the produc-
tion of infectious J6/JFH-1 chimeric virus is reduced following
FIG 6 Redistribution of the TGN to the sites ofHCV assembly. Huh7 cells were infectedwith JFH-1 (A, C, andD) ormock infected (B), fixed, and permeabilized
prior to staining with anti-core protein and anti-TGN46 (as described in the legend to Fig. 5), together with BODIPY for detection of lipid droplets (LDs) (A and
B), mouse anti-E2 antibody (AP33) (C), or mouse monoclonal anti-ApoE antibody (D) and appropriate secondary antibodies. Representative confocal images
are shown. Scale bar, 10 m.
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AP2M1 knockdown. The discrepancy between these studies may
reside in the differential core protein localizations in J6/JFH-1 and
JFH-1, which in turn are dictated by p7 and NS2 and suggest that
these viruses may co-opt related, yet distinct, pathways during
egress (41).
GGA silencing yielded further insights into the TGN-endo-
somal transport of HCV particles. Silencing of GGA1 reduced the
levels of intracellular virus but did not influence virus replication
or extracellular titers. These data imply that GGA1may play a role
in stabilizing intracellular virus. In this regard it is intriguing that
GGA1 (but not GGA2 or -3) plays a role in the endocytosis of the
ApoE receptor LR11/SorLA, amember of the LDL receptor family
FIG 7 NS2 is necessary, but not sufficient, to mediate TGN redistribution. Huh7 cells were infected with JFH-1 (A) or transiently transfected with a plasmid
expressing core-p7 (B), fixed, and permeabilized prior to staining for core protein and anti-TGN46, as described in the legend to Fig. 5. Huh7 cells stably
harboring a JFH-1-derivedNS3-5B subgenomic replicon (SGR) (C) or amodified version also containingNS2 (D)were fixed and permeabilized prior to staining
for NS5A with rabbit anti-NS5A polyclonal antiserum and Alexa Fluor 594-conjugated anti-rabbit secondary antibody and TGN46 as described in the legend to
Fig. 5. (E) NS2-5B subgenomic replicon-harboring cells were cured by treatment with interferon (100 units/ml for 3 weeks) and stained as described for panel C.
Huh7 cells were transfectedwith a plasmid expressing anNS2-GFP fusion (F) or pEGFP-N1 (G), fixed, and permeabilized prior to staining for TGN46with sheep
polyclonal anti-TGN46 and Alexa Fluor 594-conjugated anti-sheep secondary antibody. Representative confocal images are shown. Scale bar, 10 m.
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(31). By reducing endocytosis of ApoE, GGA1 silencing could
either inhibit the process of HCV assembly indirectly or destabi-
lize nascent intracellular particles by reducing the availability of
ApoE. Interestingly, a similar phenomenon has been reported in
GGA1-silenced cells infected with HIV (42). Silencing of GGA2
significantly reduced extracellular infectivity (Fig. 1B), suggesting
that this adaptormay linkHCV to subsequent secretory compart-
ments. Silencing of GGA3 produced an almost complete loss of
both intra- and extracellular infectivity, implicating it as an im-
portant mediator of infectious HCV virion assembly. Thus, our
observations correlate with the previously reported roles of both
the TGN and endosomes in HCV release (43).
DN Rabs with a role in controlling TGN-endosome trafficking
(Rab8b, -13, -23, -27, -32, and -33) (Fig. 2) blocked the release of
infectious HCV particles, while those involved in internalization/
endocytic pathways (e.g., Rab3A, -7, -9, -11, -35, and -37) dis-
played little effect (Fig. 2). Rab8b, -32, and -33 regulatemedial and
post-TGN trafficking, while Rab13 controls tight junction biogen-
esis through TGN-mediated transport (44). Surprisingly, Rab11,
known to mediate recycling endosome transport (45), did not
influence HCV secretion in our assays despite an earlier siRNA
screen identifying a role during secretion of infectious HCV (46).
Again, these previous studies differed from ours by assessing the
release of chimeric Jc1 (J6/JFH-1), which routinely gives titers up
to 1,000-fold higher than those of JFH-1 (24, 47).We propose that
different HCV subtypes/genotypes may follow subtly altered
pathways during virus egress.
We further demonstrate that VLDL secretion is unaffected by
silencing of the DNRabs and TGN-endosome adaptors that block
HCV egress (Fig. 3), while inhibition of ApoE secretion using
monensin does not impair core protein release (Fig. 4). This
would support a postrelease association between HCV particles
and VLDL, rather than the formation of cosecreted, hybrid “lipo-
viral particles,” in agreement with the dynamic transfer of HCV
infectivity between VLDL and chylomicron compartments within
patients (48). This suggests that proteins required for VLDL as-
sembly, including ApoB, ApoE, and microsomal triglyceride
transfer protein (MTP), contribute specifically to virion assembly
rather than to subsequent virion release from cells although they
may also be incorporated into infectious virions (49, 50).
Finally, we observed that the TGN membranes and compo-
nents redistribute to LD-, ApoE-, and core protein-positive com-
partments inHCV-infected cells. The TGN redistribution was de-
pendent upon the NS2 protein, but only in the context of a
functional replicase, suggesting that NS2 interactions with other
nonstructural components mediate the formation of these modi-
fied compartments. Consistent with this finding, NS2 has been
shown to play a central role during HCV particle assembly and
release through its interactionswith both structural and nonstruc-
tural proteins in close proximity to LDs (7–10). Our data indicate
that the redistribution of TGN components to virus assembly sites
may be a critical outcome of such interactions.
In conclusion, our results strongly support the idea that the
TGN and associated endosomal compartments represent a major
route for the trafficking and release of infectious HCV particles
from Huh7 cells, which occur independently of VLDL secretion.
Moreover, the virus appears to actively modulate these compart-
ments, bringing components of the TGN to the sites of virus as-
sembly through the action of NS2. These data provide further
evidence that the mechanism of HCV release requires not only
FIG 8 NS2 serine 168 is not required for TGN redistribution. Huh7 cells stably harboring G418-resistant genotype 1b FK5.1 (culture-adapted) subgenomic
replicons (SGRs) were fixed and permeabilized prior to costaining with a rabbit anti-NS5A antibody and sheep anti-TGN46 antibody, followed by labeling with
Alexa Fluor 488-conjugated anti-rabbit and Alexa Fluor 594-conjugated anti-sheep secondary antibodies. Subgenomic replicon-positive cells are highlighted
with a white asterisk in the nucleus. Representative confocal images are shown. Scale bar, 10 m.
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LD-associated endoplasmic reticulum (ER) but also membrane
compartments involved in the later secretory pathway. Future
studies should focus on elucidating the interactions between viral
and host proteins that allow HCV to usurp this pathway.
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